Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA Approves Generic Version Of Teva’s Blockbuster Drug

By Meagan Parrish | October 9, 2017

The U.S. Food And Drug Administration is keeping its promise to support competition for generic complex drugs.

But for Teva Pharmaceuticals, that push has generated bad news. Last week, the FDA announced that it’s approving Mylan’s generic version of Copaxone — Teva’s best-selling multiple-sclerosis drug.

Upon news the Mylan’s generic version had been given a green light, Mylan’s stocks soared by 16 percent, while Teva’s shares plummeted by 15 percent.

Although Teva is the world’s largest producer of generic pharmaceuticals, its brand-name Copaxone, an injectible drug, has been a windfall for the company. In the second quarter of this year, Copaxone generated $1.02 billion of the company’s $5.63 billion global sales.

The news came as a surprise and presents Teva with another challenge as the company struggles with pricing pressure on its generics business, no clear path to recovery and planned layoffs for 7,000 employees.

Mylan announced that it will soon begin shipping its 20 mg and 40 mg versions of Copaxone — called Glatiramer Acetate — and that the FDA indicated that it might have exclusive rights to the drug for 180 days.

Teva responded to the news by stating that any launch of a generic version of Copaxone while the a “final resolution of the pending patent appeals….should be considered an ‘at-risk’ launch, which could subject Mylan to significant damages.”

One analyst told Bloomberg that if a generic version of Copaxone becomes available it will pressure the price of Teva’s drug and likely result in volume loss for the company.  


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE